PT3129018T - Tratamento de nafld e nash - Google Patents

Tratamento de nafld e nash

Info

Publication number
PT3129018T
PT3129018T PT157282229T PT15728222T PT3129018T PT 3129018 T PT3129018 T PT 3129018T PT 157282229 T PT157282229 T PT 157282229T PT 15728222 T PT15728222 T PT 15728222T PT 3129018 T PT3129018 T PT 3129018T
Authority
PT
Portugal
Prior art keywords
nafld
nash
treatment
Prior art date
Application number
PT157282229T
Other languages
English (en)
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3129018(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of PT3129018T publication Critical patent/PT3129018T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT157282229T 2014-04-11 2015-04-10 Tratamento de nafld e nash PT3129018T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11

Publications (1)

Publication Number Publication Date
PT3129018T true PT3129018T (pt) 2020-01-15

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157282229T PT3129018T (pt) 2014-04-11 2015-04-10 Tratamento de nafld e nash

Country Status (26)

Country Link
US (7) US9381181B2 (pt)
EP (1) EP3129018B1 (pt)
JP (1) JP6865038B2 (pt)
KR (1) KR102374499B1 (pt)
CN (1) CN106163508A (pt)
AU (1) AU2015243239B2 (pt)
BR (1) BR112016023269A8 (pt)
CA (1) CA2944139C (pt)
CL (1) CL2016002517A1 (pt)
CY (1) CY1122602T1 (pt)
DK (1) DK3129018T3 (pt)
EA (1) EA036704B1 (pt)
ES (1) ES2764467T3 (pt)
HR (1) HRP20192299T1 (pt)
IL (1) IL248193B (pt)
LT (1) LT3129018T (pt)
MX (1) MX369921B (pt)
NZ (1) NZ724740A (pt)
PH (1) PH12016501978A1 (pt)
PL (1) PL3129018T3 (pt)
PT (1) PT3129018T (pt)
RS (1) RS59637B1 (pt)
SG (1) SG11201608077PA (pt)
SI (1) SI3129018T1 (pt)
UA (1) UA121208C2 (pt)
WO (1) WO2015157697A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
MX2011004077A (es) * 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
NO2424356T3 (pt) 2009-04-29 2018-01-20
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
ES2661217T3 (es) 2009-06-15 2018-03-28 Amarin Pharmaceuticals Ireland Limited Composiciones y métodos para reducir los triglicéridos sin aumentar los niveles de LDL-C en un sujeto en terapia simultánea con estatinas
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
MA50258A1 (fr) 2012-06-29 2023-07-31 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'un événement cardiovasculaire chez un sujet soumis à un traitement par une statine
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
DK3129018T3 (da) * 2014-04-11 2020-01-20 Cymabay Therapeutics Inc Behandling af NAFLD og NASH
JP6687544B2 (ja) 2014-05-28 2020-04-22 チルドレンズ ホスピタル メディカル センター 前駆細胞を指向性分化によって胃組織に変換するための方法及びシステム
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
WO2016154258A1 (en) * 2015-03-26 2016-09-29 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
WO2016173923A1 (en) 2015-04-28 2016-11-03 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2017192997A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
NZ753051A (en) * 2016-11-04 2023-03-31 Children’S Hospital Medical Center Liver organoid compositions and methods of making and using same
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
JP7068305B2 (ja) 2016-12-05 2022-05-16 チルドレンズ ホスピタル メディカル センター 結腸オルガノイドならびにその作製方法および使用方法
TWI762634B (zh) 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20200276178A1 (en) 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
WO2019083070A1 (ko) * 2017-10-27 2019-05-02 주식회사 삼양사 비알코올성 지방간 질환의 예방 또는 개선용 조성물
IL275002B2 (en) 2017-12-06 2024-04-01 Basf As Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3700518A4 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited METHODS FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
EA202191379A1 (ru) * 2018-11-16 2021-08-06 Саймабэй Терапьютикс, Инк. Комбинированное лечение nafld и nash
EP3880187A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
WO2021097034A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
WO2021097027A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
KR20230024277A (ko) * 2020-05-13 2023-02-20 테른스 파마슈티칼스, 인크. 간 장애의 조합 치료
EP4326244A1 (en) 2021-04-21 2024-02-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
WO2022238450A1 (en) * 2021-05-11 2022-11-17 Genfit Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
AU725262B2 (en) 1996-02-14 2000-10-12 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
ATE542793T1 (de) 2003-09-19 2012-02-15 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
PL1725234T5 (pl) 2004-03-05 2016-06-30 Univ Pennsylvania Sposoby leczenia zaburzeń lub chorób związanych z hiperlipidemią i hipercholesterolemią ze zminimalizowaniem efektów ubocznych
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
MX2011004077A (es) 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA201691039A1 (ru) 2013-11-20 2016-11-30 Саймабэй Терапьютикс, Инк. Лечение гомозиготной семейной гиперхолестеринемии
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
DK3129018T3 (da) 2014-04-11 2020-01-20 Cymabay Therapeutics Inc Behandling af NAFLD og NASH
MX2016017081A (es) 2014-06-26 2017-05-01 Cymabay Therapeutics Inc Tratamiento de hipertrigliceridemia grave.

Also Published As

Publication number Publication date
EA036704B1 (ru) 2020-12-10
US20190142776A1 (en) 2019-05-16
US20200009092A1 (en) 2020-01-09
CA2944139A1 (en) 2015-10-15
EP3129018A1 (en) 2017-02-15
US11179359B2 (en) 2021-11-23
PL3129018T3 (pl) 2020-05-18
KR20160136451A (ko) 2016-11-29
US20160324812A1 (en) 2016-11-10
JP6865038B2 (ja) 2021-04-28
DK3129018T3 (da) 2020-01-20
US20150290154A1 (en) 2015-10-15
BR112016023269A2 (pt) 2017-08-15
CN106163508A (zh) 2016-11-23
US9381181B2 (en) 2016-07-05
US20210038546A1 (en) 2021-02-11
US10342770B2 (en) 2019-07-09
EP3129018B1 (en) 2019-10-23
SG11201608077PA (en) 2016-10-28
RS59637B1 (sr) 2020-01-31
MX369921B (es) 2019-11-26
CY1122602T1 (el) 2021-03-12
HRP20192299T1 (hr) 2020-03-06
WO2015157697A1 (en) 2015-10-15
AU2015243239A1 (en) 2016-10-20
LT3129018T (lt) 2020-01-10
UA121208C2 (uk) 2020-04-27
KR102374499B1 (ko) 2022-03-14
ES2764467T3 (es) 2020-06-03
SI3129018T1 (sl) 2020-02-28
US20180008566A1 (en) 2018-01-11
US20180228752A1 (en) 2018-08-16
JP2017513836A (ja) 2017-06-01
US10188620B2 (en) 2019-01-29
CA2944139C (en) 2020-11-03
US9616039B2 (en) 2017-04-11
PH12016501978A1 (en) 2016-12-19
EA201692050A1 (ru) 2017-01-30
US9962346B2 (en) 2018-05-08
CL2016002517A1 (es) 2017-05-05
US10722483B2 (en) 2020-07-28
NZ724740A (en) 2019-11-29
BR112016023269A8 (pt) 2021-06-29
AU2015243239B2 (en) 2019-11-14
IL248193B (en) 2019-03-31
MX2016013375A (es) 2017-02-15

Similar Documents

Publication Publication Date Title
SG11201608077PA (en) Treatment of nafld and nash
IL250415B (en) Antibodies against pd-l and methods of using them
IL252839A0 (en) Treatment of boils
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
ZA201605639B (en) Hppd variants and methods of use
ZA201606243B (en) Hppd variants and methods of use
GB201404470D0 (en) Therapeutic methods and materials
IL282482A (en) Variants of protoxin-II and methods of use
IL282508A (en) Variants of protoxin-II and methods of use
GB201416832D0 (en) Methods of treatment
GB201408297D0 (en) Treatment of cancer
GB201511799D0 (en) Composition and methods of treatment
GB201605127D0 (en) Composition and methods of treatment
GB201417248D0 (en) Compostion and methods of treatment
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411150D0 (en) Novel aptamers and therapeutic uses thereof
ZA201802201B (en) Novel formulation and treatment methods
GB201417456D0 (en) Treatment of cancer
GB201404265D0 (en) Respiratory analysis and treatment
GB201419559D0 (en) Therapeutic compositions and methods
GB201410695D0 (en) Uses of oligouronates in cancer treatment
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201416797D0 (en) Contianer and method of use thereof
GB201409262D0 (en) Hair treatment compositions and methods
GB201409362D0 (en) Treatment of cancer